Novo Nordisk A/S (ADR)  

(Public, NYSE:NVO)   Watch this stock  
Find more results for NVO
42.85
-0.70 (-1.61%)
Real-time:   11:07AM EDT
NYSE real-time data - Disclaimer
Currency in USD
Range 42.50 - 42.99
52 week 30.89 - 57.41
Open 42.71
Vol / Avg. 483,755.00/1.66M
Mkt cap 85.94B
P/E 17.89
Div/yield 0.67/3.13
EPS 2.40
Shares 1.92B
Beta 0.66
Inst. own 9%

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin 35.70% 33.93%
Operating margin 47.41% 43.33%
EBITD margin - 46.18%
Return on average assets 42.49% 40.06%
Return on average equity 95.21% 82.23%
Employees 41,636 -
CDP Score - A

Address

Novo Alle
BAGSVAERD, 2880
Denmark
+45-44-448888 (Phone)
+45-44-436633 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Officers and directors

Goran A. Ando M.D. Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
Lars Fruergaard Joergensen President, Chief Executive Officer
Age: 50
Bio & Compensation  - Reuters
Jeppe Christiansen Vice Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Jesper Brandgaard Chief Financial Officer, Executive Vice President
Age: 53
Bio & Compensation  - Reuters
Maziar Mike Doustdar Executive Vice President, International Operations
Age: 46
Bio & Compensation  - Reuters
Mads Krogsgaard Thomsen Chief Science Officer, Executive Vice President
Age: 56
Bio & Compensation  - Reuters
Henrik Ehlers Wulff Executive Vice President, Product Supply
Age: 46
Bio & Compensation  - Reuters
Doug Langa Senior Vice President, Head of North America Operations, President of Novo Nordisk Inc.
Bio & Compensation  - Reuters
Liselotte Hyveled Director, Employee Representative
Age: 51
Bio & Compensation  - Reuters
Kasim Kutay Director
Bio & Compensation  - Reuters